FBXO17 Inhibitors

MG132 is a potent proteasome inhibitor that can indirectly inhibit FBXO17 by preventing the degradation of proteins targeted by the FBXO17-containing SCF (Skp1-Cullin-F-box) E3 ubiquitin ligase complex. As a result, the accumulation of these substrates could lead to a functional inhibition of FBXO17 due to substrate overload and feedback inhibition.

Pyr41 is an inhibitor of the ubiquitin-activating enzyme E1. By preventing the initial step of ubiquitination, Pyr41 can indirectly inhibit FBXO17's function in the ubiquitination process because FBXO17 relies on E1 for activation of ubiquitin molecules that it subsequently transfers to its substrates.

MLN4924 inhibits the NEDD8-activating enzyme (NAE), which is crucial for the neddylation process that activates the Cullin-RING ligases (CRLs) to which FBXO17 belongs. Inhibition of NAE leads to reduced neddylation of Cullin, thereby inhibiting the activity of FBXO17 as part of the SCF complex.

Lactacystin is another proteasome inhibitor that can lead to the accumulation of FBXO17 substrates by inhibiting their degradation. This accumulation can functionally inhibit the activity of FBXO17 by disrupting its ability to target new substrates for ubiquitination.

Chloroquine raises the pH in lysosomes, inhibiting lysosomal enzymes. Since lysosomal degradation is an alternative pathway for proteins ubiquitinated by FBXO17, inhibiting this pathway can cause the accumulation of FBXO17 substrates, indirectly inhibiting FBXO17 function due to a backlog of substrates.

Epoxomicin is a selective proteasome inhibitor that, like MG132 and Lactacystin, can cause an accumulation of FBXO17 substrates, leading to functional inhibition of FBXO17 by preventing it from efficiently ubiquitinating additional substrates.

Bortezomib, a clinical proteasome inhibitor, can lead to the accumulation of ubiquitinated substrates of FBXO17, thus indirectly inhibiting the functional activity of FBXO17 by overwhelming the protein with non-degraded substrates.

Carfilzomib is a proteasome inhibitor that leads to the buildup of proteins meant to be degraded via the ubiquitin-proteasome system, indirectly impeding FBXO17's function due to excessive accumulation of its substrates.

ONX 0914 is an inhibitor of the immunoproteasome subunit LMP7, which can result in the accumulation of FBXO17 substrates, thus indirectly inhibiting FBXO17's function in substrate ubiquitination.

Leupeptin is an inhibitor of thiol proteases, which are involved in the degradation of proteins. Even though FBXO17 is part of the ubiquitin-mediated degradation pathway, inhibition of downstream proteases can lead to an accumulation of its substrates, thereby indirectly inhibiting FBXO17.